Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | I817L |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | KIT I817L lies within the protein kinase domain of the Kit protein (UniProt.org). I817L has been identified in the scientific literature (PMID: 26424760, PMID: 29191620, PMID: 19369623), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Feb 2025). |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT exon17 KIT I817L |
Transcript | NM_000222.3 |
gDNA | chr4:g.54733157A>C |
cDNA | c.2449A>C |
Protein | p.I817L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001385290.1 | chr4:g.54733157A>C | c.2449A>C | p.I817L | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54733157A>C | c.2449A>C | p.I817L | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT I817L | acral lentiginous melanoma | predicted - sensitive | Nilotinib | Case Reports/Case Series | Actionable | In a Phase II trial, Tasigna (nilotinib) treatment resulted in an overall response rate of 16.7% (7/42, 1 complete and 6 partial responses) and a disease control rate of 57.1% in melanoma patients harboring KIT mutations (n=25), amplification (n=15), or both (n=2), including a partial response with a duration of response of 55 weeks in a patient with acral melanoma harboring KIT I817L (PMID: 26424760; NCT01099514). | 26424760 |